-
EAU25 | Final Survival Results from SPCG-13 Trial: Surveillance vs. Docetaxel After Radiotherapy in High-Risk Prostate Cancer
In a Game Changer Session at EAU25, Prof. Kellokumpu-Lehtinen Pirkko-Liisa presented the 10-year follow-up from the Scandinavian Prostate Cancer Study Group-13 trial (SPCG-13), exploring adjuvant docetaxel versus surveillance following curative…
-
Can a short video ease the mind of a worried parent?
At EAU25, Dr. Mehmet Cetin from Marmara University School of Medicine (Istanbul) presented a prospective randomized controlled study evaluating the impact of video-based informed consent on the anxiety levels of…
-
APASL China Voice | Dr. Rong Fan: The Application of Cell-Free DNA Testing in Early Hepatocellular Carcinoma Surveillance
In recent years, cell-free DNA (cfDNA)—a novel biomarker—has drawn increasing attention for its potential in early prediction and precise diagnosis of HCC. On March 29, during a parallel session at…
-
APASL 2025 | Dr. Yinying Lu’s Team Unlocks New Multidimensional Strategies in Liver Cancer Treatment
Among the notable contributions, the research team led by Dr. Yinying Lu from the Fifth Medical Center of the PLA General Hospital presented several significant findings on liver cancer treatment.…
-
Allogeneic Transplant Outcomes in Severe Aplastic Anemia: What Role Does Donor Type Play?
At the EBMT 2025 Annual Meeting, Dr. Juan Montoro Gómez (La Fe University and Polytechnic Hospital, Valencia) presented key findings from a comparative study led by the SAAWP of the…
-
Relapsed B-ALL Post CAR-T Therapy: Addressing a Growing Clinical Challenge | EBMT 2025
In his EBMT 2025 presentation, Prof. Alessandro Rambaldi (University of Milan / ASST Papa Giovanni XXIII, Bergamo) offered valuable insight into one of the most pressing issues in hematologic oncology:…
-
Late Effects After Auto-HSCT in Autoimmune Diseases: A Call for Long-Term Monitoring
At the EBMT 2025 annual meeting, Dr. Kirill Kirgizov presented findings from a comprehensive retrospective survey (GS2-10) on late complications following autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases…
-
Clonal Hematopoiesis in Pediatric HCT Survivors: New Insights from Dr. Konradin Müskens at EBMT 2025
At the 51st EBMT Annual Meeting, Dr.Konradin Müskens (Prinses Máxima Centrum voor kinderoncologie, Netherlands) presented findings from the GS2-4 session on “Prevalence and Origin of Clonal Hematopoiesis in Long-Term Survivors…
Connecting Medical Expertise through Media